Methods for the treatment of bradyphrenia in parkinson's disease
AssigneeMount Sinai School of Medicine of the City University of New York
InventorRam Kaminski
Life of this patent
Estimating the term…
Abstract
Neuropsychiatric symptoms of Parkinson's Disease and particularly the symptoms of apathy-amotivation and mental slowing can be ameliorated by treating a patient suffering from Parkinson's Disease with a histamine H.sub.2 -antagonist that passes the blood brain barrier. Suitable H.sub.2 -antagonists include famotidine and ranitidine. The H.sub.2 -antagonists may be co-administered with other compounds such as histamine H,-antagonists which are known to be useful in the treatment of Parkinson's Disease, and can be formulated with such other compounds into a therapeutic composition.
Claims14
A method for treating the symptoms of bradyphrenia in a patient suffering from Parkinson's Disease comprising administering to the patient a compound selected from the group consisting of famotidine, ranitidine, cimetidine, nizatidine, omeprazole, tiotidine, and aminofurazan compounds, that crosses the blood brain barrier in an amount effective to ameliorate the symptoms of bradyphrenia.
A method for treating the symptoms of bradyphrenia in a patient suffering from Parkinson's Disease comprising administering to the patient a compound selected from the group consisting of famotidine, ranitidine and cimetidine that crosses the blood brain barrier in an amount effective to ameliorate the symptoms of bradyphrenia.
A method for treating the symptoms of bradyphrenia in a patient suffering from Parkinson's Disease comprising administering to the patient a compound selected from the group consisting of famotidine, famotidine homologs and famotidine isomers that crosses the blood brain barrier in an amount effective to ameliorate the symptoms of bradyphrenia.
Dependencies are inferred from the claim text.